We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
PRPH

Price
0.34
Stock movement up
+0.01 (1.61%)
Company name
ProPhase Labs Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Diagnostics & Research
Markedsværdi
13.92M
Ent værdi
67.10M
Pris/omsætning
1.09
Pris/bog
0.37
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-45.70%
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
44.90%
1 års afkast
-88.60%
3 års afkast
-70.29%
5 års afkast
-33.80%
10 års afkast
-13.45%
Senest opdateret: 2025-09-15

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UDBYTTE

PRPH betaler ikke udbytte

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning1.09
Pris til egenkapital0.37
EV i forhold til salg5.26

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier41.54M
EPS (TTM)-1.45
FCF pr. aktie (TTM)-0.87

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)12.75M
Bruttofortjeneste (TTM)-4.13M
Driftsindkomst (TTM)-35.41M
Nettoindkomst (TTM)-27.76M
EPS (TTM)-1.45
EPS (1 år frem)-

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-32.38%
Driftsmargin (TTM)-277.69%
Fortjenstmargin (TTM)-217.64%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter501.00K
Nettotilgodehavender31.64M
Omsætningsaktiver i alt42.23M
Goodwill5.23M
Immaterielle aktiver10.40M
Ejendomme, anlæg og udstyr18.09M
Sum aktiver91.81M
Kreditor15.46M
Kortfristet/nuværende langsigtet gæld29.59M
Summen af kortfristede forpligtelser28.70M
Sum gæld53.68M
Aktionærernes egenkapital38.13M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-14.18M
Investeringsudgifter (TTM)2.45M
Fri pengestrøm (TTM)-16.63M
Udbetalt udbytte (TTM)7.60M

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-72.80%
Afkast af aktiver-30.23%
Afkast af investeret kapital-42.68%
Kontant afkast af investeret kapital-25.57%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning0.32
Daglig høj0.35
Daglig lav0.32
Daglig volumen694K
Højeste gennem alle tider22.13
1 års analytiker estimat13.80
Beta-0.47
EPS (TTM)-1.45
Udbytte pr. aktie-
Ex-div dato24 May 2022
Næste dato for resultatpræsentation6 Nov 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
PRPHS&P500
Nuværende prisfald fra top notering-98.49%-1.46%
Højeste prisfald-98.93%-56.47%
Højeste efterår dato4 Feb 20259 Mar 2009
Gennemsnitlig fald fra toppen-76.64%-10.99%
Gennemsnitlig tid til nyt højdepunkt199 days12 days
Maks. tid til nyt højdepunkt6904 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

OPLYSNINGER OM VIRKSOMHEDEN
PRPH (ProPhase Labs Inc) company logo
Markedsværdi
13.92M
Markedsværdi kategori
Small-cap
Beskrivelse
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Personale
96
Investor relationer
-
SEC-indsendelser
Adm. direktør
Ted William Karkus
Land
USA
By
Doylestown
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...

iO Charts is a Seeking Alpha partner

FORSTÅ FORRETNINGEN
Loading...